Talimogene laherparepvec in the treatment of melanoma

Bibliography

• CRUK. 2014. Available from: http://publications.cancerresearchuk.org/cancerstats/statsskin/keyfactsskin.html
   Google Scholar
• Mayer JE, Swetter SM, Fu T, et al. Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part II. Screening, education, and future directions. J Am Acad Dermatol 2014;71(4):611 e1-611 e10; quiz 621-2
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108
   PubMed Web of Science ®Google Scholar
• Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365(9460):687-701
   PubMed Web of Science ®Google Scholar
• Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011;47(10):1476-83
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(Suppl 1):S11-14
   PubMed Web of Science ®Google Scholar
• Young K, Minchom A, Larkin J. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol 2012;8(5):499-507
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107-14
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102(12):1724-30
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Cianci R, Pagliari D, et al. The Immune Response to Tumors as a Tool toward Immunotherapy. Clin Dev Immunol 2011;2011:894704
   PubMed Web of Science ®Google Scholar
• Bennett WT, Pandolfi F, Grove BH, et al. Dominant rearrangements among human tumor-infiltrating lymphocytes. Analysis of T-cells derived from 32 patients with melanoma, lung, and renal cell carcinoma. Cancer 1992;69(9):2379-84
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MCJr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77(7):1303-10
   PubMed Web of Science ®Google Scholar
• Hishii M, Andrews D, Boyle LA, et al. In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA 1997;94(4):1378-83
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:8-595-601
   Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18(7):2039-4
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long G.V, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372(26):2521-32
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16(8):908-1
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16(4):375-84
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372(21):2006-17
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558-62
   PubMed Web of Science ®Google Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007;15(4):651-9
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30(7):658-70
   PubMed Web of Science ®Google Scholar
• Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model. Cancer Gene Ther 1997;4(2):139-44
   PubMed Web of Science ®Google Scholar
• Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16(9):1637-42
   PubMed Web of Science ®Google Scholar
• Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011;19(10):1913-22
   PubMed Web of Science ®Google Scholar
• Advani SJ, Weichselbaum RR, Whitley RJ, et al. Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect 2002;8(9):551-63
   PubMed Web of Science ®Google Scholar
• Yoon SS, Nakamura H, Carroll NM, et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14(2):301-11
   PubMed Web of Science ®Google Scholar
• Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992;89(8):3266-70
   PubMed Web of Science ®Google Scholar
• Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250(4985):1262-6
   PubMed Web of Science ®Google Scholar
• Randazzo BP, Bhat MG, Kesari S, et al. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 1997;108(6):933-7
   PubMed Web of Science ®Google Scholar
• MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001;357(9255):525-6
   PubMed Web of Science ®Google Scholar
• Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999;73(8):6319-26
   PubMed Web of Science ®Google Scholar
• Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000;74(8):3832-41
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7(10):867-74
   PubMed Web of Science ®Google Scholar
• Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10(3):385-93
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10(4):292-303
   PubMed Web of Science ®Google Scholar
• Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001;98(11):6396-401
   PubMed Web of Science ®Google Scholar
• York IA, Roop C, Andrews DW, et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994;77(4):525-35
   PubMed Web of Science ®Google Scholar
• Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375(6530):411-15
   PubMed Web of Science ®Google Scholar
• Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. Embo J 1996;15(17):4759-66
   PubMed Web of Science ®Google Scholar
• Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 1998;72(9):7005-11
   PubMed Web of Science ®Google Scholar
• Taneja S, MacGregor J, Markus S, et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001;98(15):8804-8
   PubMed Web of Science ®Google Scholar
• Hercus TR, Thomas D, Guthridge MA, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. 2009;114:1289-98
   Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90(8):3539-43
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014;2:11
   PubMedGoogle Scholar
• Chahlavi A, Rabkin S, Todo T, et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999;6(10):1751-8
   PubMed Web of Science ®Google Scholar
• Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12(22):6737-47
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27(34):5763-71
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010;16(15):4005-15
   PubMed Web of Science ®Google Scholar
• Sivendran S, Pan M, Kaufman HL, et al. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther 2010;10(7):1145-53
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691-7
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hoos A, Todo T. Novel efficacy criteria for antitumor activity using the example of ipilimumabm an anti-CTLA-4 monoclonal antibody. J Clin Oncol 2008;26:Suppl; abstr 3008
   Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17(3):718-30
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62(21):6070-9
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem M, Ingemar R. Andtbacka, Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2015;33(suppl):abstr 9063^
   Google Scholar
• Amgen. MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma. Available from: https://clinicaltrials.gov/show/NCT02263508.%20NLM%20identifier:%20NCT02263508%20-%20See%20more%20at:%20. 2014; [Last accessed 13 March 2015]
   Google Scholar
• Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monocolonal antibody MK-3475 in 411 patients with melanoma. J Clin Oncol 2014;32(5s):suppl; abstr LBA9000
   Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568-71
   PubMed Web of Science ®Google Scholar
• White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15(12):911-20
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61(7):1019-31
   PubMed Web of Science ®Google Scholar
• Pandha HS, Heinemann L, Simpson GR, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009;15(19):6158-66
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6(8):879-85
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014;6(226):226ra32
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203(7):1651-6
   PubMed Web of Science ®Google Scholar
• Knight DA, Ngiow SF, Li M, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013;123(3):1371-81
   PubMed Web of Science ®Google Scholar
• Roulstone V, Pedersen M, Kyula J, et al. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Mol Ther 2015;23(5):931-42
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Brahmer JR. Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res 2015;21(5):976-84
   PubMed Web of Science ®Google Scholar
• Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002;9(12):1062-7
   PubMed Web of Science ®Google Scholar
• Castleton A, Dey A, Beaton B, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 2014;123(9):1327-35
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000;60(11):2790-5
   PubMed Web of Science ®Google Scholar
• Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13(11):1325-34
   PubMed Web of Science ®Google Scholar
• Ilett E, Kottke T, Donnelly O, et al. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Ther 2014;22(10):1851-63
   PubMed Web of Science ®Google Scholar
• Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14(21):7127-37
   PubMed Web of Science ®Google Scholar